
ALK has secured the rights to a technology it will use to develop a tablet against peanut allergy, which will be one of the most important growth drivers in the years post-2025, according to the Danish allergy company.
The technology in question is a fast-dissolve tablet formulation dubbed Zydis, which Catalent is behind. ALK has used this technology before, as the company signed a deal with Catalent many years ago to develop its respiratory tablet portfolio.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app